Airflow restriction and ongoing respiratory symptoms are symptoms of chronic obstructive pulmonary disease (COPD), a degenerative lung condition. It includes ailments like chronic bronchitis and emphysema that are mostly brought on by prolonged exposure to dangerous particles or gasses, most frequently by smoking. The illness causes inflammation and lung tissue and airway damage, which makes breathing difficult and causes coughing, wheezing, and increased mucus production. Because it frequently results in weariness and decreased physical activity, COPD has a major negative influence on quality of life.
Global Chronic Obstructive Pulmonary Disease (COPD) Market Driving Factors and Challenges
Driving Factors- Rising healthcare expenditures are providing facilities for COPD in developing countries, and rising public awareness in undeveloped and developing areas is also anticipated to fuel market growth. Furthermore, the increase in R&D spending by the government and large corporations is one of the key elements expected to drive the development of the chronic obstructive pulmonary disease sector. In cases of emphysema, the alveoli in the lungs are damaged. The lungs enlarge and the airflow becomes more difficult due to the stretched alveolar walls. Chronic bronchitis irritates the bronchial airways in the lungs.
Furthermore, Among the combination treatments are LABA-ICS, triple therapy, LAMA-ICS, and further combination medications. Combination therapy is becoming more and more popular because it works better than using bronchodilators and corticosteroids separately. The global market for chronic obstructive pulmonary disease is also expected to grow faster in the upcoming years due in large part to an increase in the number of patients who were successfully treated with combination therapy but did not show signs of recovery with bronchodilators or corticosteroid treatments.
Challenges- Growth and expansion in the chronic obstructive pulmonary disease (COPD) market are impeded by a number of noteworthy obstacles. A significant problem is the underdiagnosis and delayed diagnosis of COPD, since many patients wait until the illness has worsened before seeking treatment, which results in lost chances for early intervention. Effective patient care and adherence may also be hampered by the complexity of managing COPD, which frequently calls for a multidisciplinary approach and a variety of treatment alternatives. Many patients may not be able to obtain new therapies due to the high prices and the financial strain of managing chronic diseases, especially in low-income areas.
Impact of COVID-19 on Global Chronic Obstructive Pulmonary Disease (COPD) Market
The COVID-19 pandemic has had a significant impact on the global market for chronic obstructive pulmonary disease (COPD), posing both opportunities and difficulties. People with COPD were especially vulnerable during the pandemic because to their underlying respiratory conditions, which increased hospitalizations and the focus on respiratory health. Healthcare systems frequently disrupted routine COPD care and management due to prioritizing COVID-19 reactions, which affected patients' access to drugs and exacerbated their conditions.
Global Chronic Obstructive Pulmonary Disease (COPD) Market Key Players:
The market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as: Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott, Boehringer Ingelheim International GmbH, Biogen, Teva Pharmaceutical Industries Ltd, Others.
Global Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation:
By Type: Based on the Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Chronic Bronchitis, Emphysema.
By Treatment Type: Based on the Treatment Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Bronchodilator monotherapy, short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), anti-cholinergic agents, anti-inflammatory drugs, oral and inhaled corticosteroids, anti-leukotrienes, surgery, lung volume reduction surgery (LVRS), lung transplant, bullectomy and others.
By End User: Based on the End User, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Hospitals, Homecare Settings, Clinics, Others
By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.